Navigation Links
PET scans can accurately detect a breast tumor's response to chemotherapy
Date:9/25/2007

Barcelona, Spain: Researchers in Australia have shown that positron emission tomography (PET) that uses a radioactive sugar molecule is more useful than mammography and ultrasound in predicting a breast tumours response to chemotherapy and, therefore, the patients ultimate likelihood of survival.

In research presented today (Tuesday) at the European Cancer Conference (ECCO 14) in Barcelona, Dr Vinod Ganju reported that when the scanning procedure was used to measure the accumulation of radioactive glucose fluorodeoxyglucose (FDG) in tumour tissue from patients with locally-advanced breast cancer before and after preoperative chemotherapy, women who had the highest accumulation at the beginning and who then had the highest percentage drop in accumulation after four cycles of chemotherapy were more likely to have a complete response to their treatment i.e. no tumour cells remaining in the final tumour resection specimen. However, measurements taken using mammography or ultrasound were not able to predict a pathological response accurately.

FDG-PET works by injecting a sugar molecule (FDG), tagged with a radioactive tracer, into the patient. The molecule is metabolically active and concentrates in tumour tissues where it emits energy that PET scanning can detect. PET measures the standard uptake values (SUVs), in other words, how much FDG has accumulated in the tumour. If the SUVs drop after chemotherapy, this shows that there are fewer, or no, cancer cells available where the FDG can accumulate. This study suggests that tumours with high initial SUVs seem to be more sensitive to chemotherapy, thereby giving a better chance of achieving a reduction or complete removal of the cancer.

Dr Ganju, a medical oncologist for Monash Oncology Research Institute (MORI) and Monash Breast Cancer Research Consortium, Monash Medical Centre, Melbourne, Australia, said: In our study, we were able to show that patients who had higher baseline SUVs and a greater reduction in SUV at the second PET scan, were more likely to respond to the chemotherapy and achieve a complete pathological response. Patients who achieve a complete pathological response are more likely to survive and have a better prognosis.

The researchers recruited 47 women with locally advanced breast cancer to their study, and they were able to evaluate data from 44 of these women. The patients were randomly assigned to receive either fluorouracil, epirubicin, cyclophosphamide (FEC) followed by docetaxel, or docetaxel followed by FEC. They were assessed at the start by PET scans, physical examination, mammography, ultrasound and tumour biopsy, and again after four cycles of chemotherapy. The initial SUVs and the percentage reduction in SUVs after chemotherapy were correlated to pathological response (complete, partial or no response) as assessed by examination of biopsy samples.

Nine women had a complete pathological response (pCR), 15 had a partial response (pPR) and 20 less than optimal pathological response (NR) to chemotherapy. Women who had a pCR were significantly more likely to have higher SUVs before chemotherapy than NR women (an average of 9.7 versus 6.4 on the SUV measurement scale). The percentage reduction in SUVs after chemotherapy was also significant, with SUVs in pCR women reducing by an average of 83.3 percent compared to 50.4 percent in NR women.

Dr Ganju said: This study shows that women with high baseline SUVs and a higher percentage reduction of SUVs after four cycles of chemotherapy are more likely to achieve a pathological complete response to neoadjuvant chemotherapy. FDG-PET appears to be an important addition to conventional imaging of women with breast cancer and may contribute significantly to a more individualised management of their disease. Currently, all patients receive the same chemotherapy regardless of their tumour characteristics. It would be very valuable to target therapies according to baseline tumour characteristics. This could spare the patient unnecessary on-going chemotherapy, or enable them to switch to a different therapy if the first was found to be ineffective.

PET technology is advancing all the time. Different tracer molecules other than glucose are available for PET studies. These may prove even more useful in the future, but most are still in the experimental stages, concluded Dr Ganju. The group is also currently correlating the results from this study with the genetic profile of the tumours.


'/>"/>

Contact: Emma Mason
wordmason@mac.com
34-932-308-834
ECCO-the European CanCer Conference
Source:Eurekalert

Related medicine news :

1. Effect of Osteosarcoma predicted by scans
2. Use of CT scans to detect lung cancer questioned
3. Brain Scans Help Predict Alzheimers Disease
4. PET Scans Found To Reveal Hidden Cancers
5. CT Scans Found To Increase The Risk Of Cancer
6. PET Scanner detects more Vaginal cancer than CT scans
7. PET scans can detect the results of cognitive behavior therapy
8. Avoid Coffee Before Undergoing PET/ CT scans
9. Brain scans show why we always have room for dessert
10. CT Scans Said to Accurately Detect Small Cancers
11. CT Scans Found To Do More Harm Than Good
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: